NovoCure (NASDAQ:NVCR) Reaches New 12-Month High Following Strong Earnings

NovoCure Limited (NASDAQ:NVCR)’s stock price reached a new 52-week high during trading on Thursday following a stronger than expected earnings report. The stock traded as high as $20.33 and last traded at $20.1390, with a volume of 912672 shares. The stock had previously closed at $15.57.

The medical equipment provider reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.20. The company had revenue of $183.58 million during the quarter, compared to analyst estimates of $172.44 million. NovoCure had a negative return on equity of 50.82% and a negative net margin of 25.66%.The firm’s revenue for the quarter was up 15.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.36) earnings per share.

Key NovoCure News

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: NovoCure reported Q2 earnings that beat expectations, with a loss of $0.13 per share versus the expected $0.33 loss, while revenue of $183.58 million also topped estimates and grew 15.6% year over year. Article Title
• Positive Sentiment: The company also issued FY 2026 revenue guidance of $710 million to $725 million, above the consensus estimate of about $704 million, which suggests management sees continued top-line momentum. Article Title
• Positive Sentiment: HC Wainwright raised its price target on NovoCure to $52 from $46 and reiterated a Buy rating, reinforcing the bullish view after the earnings release. Article Title
• Neutral Sentiment: Additional coverage highlighted NovoCure’s Q2 results and a possible technical breakout, which may be adding to investor optimism but does not change the underlying fundamentals. Article Title

Wall Street Analyst Weigh In

NVCR has been the subject of a number of research analyst reports. Evercore reiterated an “outperform” rating on shares of NovoCure in a report on Friday, May 1st. Zacks Research lowered shares of NovoCure from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Weiss Ratings raised shares of NovoCure from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 1st. JPMorgan Chase & Co. began coverage on shares of NovoCure in a research note on Monday, July 13th. They set a “neutral” rating and a $17.00 target price for the company. Finally, Wedbush reiterated a “neutral” rating and set a $18.00 price target on shares of NovoCure in a research report on Thursday, April 16th. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, NovoCure has an average rating of “Hold” and a consensus target price of $24.80.

Insider Activity

In other NovoCure news, Director Allyson J. Ocean sold 2,945 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $15.77, for a total value of $46,442.65. Following the completion of the transaction, the director owned 11,324 shares in the company, valued at $178,579.48. The trade was a 20.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Frank X. Leonard sold 34,273 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $17.93, for a total value of $614,514.89. Following the sale, the chief executive officer directly owned 459,520 shares in the company, valued at $8,239,193.60. This represents a 6.94% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 51,943 shares of company stock worth $893,171 over the last 90 days. Company insiders own 5.52% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Empowered Funds LLC purchased a new stake in NovoCure during the 4th quarter worth about $33,000. Kestra Advisory Services LLC purchased a new position in shares of NovoCure in the 4th quarter valued at about $49,000. Larson Financial Group LLC grew its position in shares of NovoCure by 662.1% during the third quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock worth $53,000 after buying an additional 3,562 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of NovoCure by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,442 shares of the medical equipment provider’s stock worth $70,000 after buying an additional 1,120 shares during the period. Finally, Acadian Asset Management LLC purchased a new stake in shares of NovoCure during the first quarter worth approximately $87,000. 84.61% of the stock is currently owned by hedge funds and other institutional investors.

NovoCure Trading Up 28.4%

The company’s fifty day moving average is $16.64 and its two-hundred day moving average is $14.12. The stock has a market cap of $2.32 billion, a price-to-earnings ratio of -13.07 and a beta of 0.94. The company has a quick ratio of 2.70, a current ratio of 2.90 and a debt-to-equity ratio of 0.71.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.